Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04208178
Title Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor positive breast cancer

Therapies

Pertuzumab + Trastuzumab

Alpelisib + Pertuzumab + Trastuzumab

Age Groups: adult senior

Additional content available in CKB BOOST